This preprint is under consideration at Medicinal Chemistry Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Benjamin E. Blass
Temple University School of Pharmacy
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2449-4503
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D1, D2, D3, D4, and D5. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson’s disease (PD), and inflammatory diseases have been linked to aberrant D3 activity. Herein, we report a series of novel D3 ligands with improved solubility over our previous lead compound, MC25-41 (2).
Keywords
Dopamine, D3 dopamine receptor, D2 dopamine receptor
This preprint is available for download as a PDF.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 15 Nov, 2021
No community comments so far
Editorial decision: Major Revision
On 25 Nov, 2021
Reviews received
Received 10 Nov, 2021
Reviewers invited
Invitations sent on 10 Nov, 2021
Editor assigned
On 29 Oct, 2021
First submitted
On 27 Oct, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Medicinal Chemistry Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Benjamin E. Blass
Temple University School of Pharmacy
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2449-4503
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 15 Nov, 2021
No community comments so far
Editorial decision: Major Revision
On 25 Nov, 2021
Reviews received
Received 10 Nov, 2021
Reviewers invited
Invitations sent on 10 Nov, 2021
Editor assigned
On 29 Oct, 2021
First submitted
On 27 Oct, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Dopamine (1) is a key neurotransmitter whose impact on pharmacological processes is mediated by a family of dopamine receptors designated D1, D2, D3, D4, and D5. Various diseases and conditions such as schizophrenia, drug abuse, depression, restless leg syndrome, Parkinson’s disease (PD), and inflammatory diseases have been linked to aberrant D3 activity. Herein, we report a series of novel D3 ligands with improved solubility over our previous lead compound, MC25-41 (2).
This preprint is available for download as a PDF.
Loading...